PLK4 has been reported to modulate sensitivity to various chemotherapeutic agents such as temozolomide in glioblastoma [58]; cisplatin in neuroblastoma [62] and oxaliplatin in colorectal cancer [32] (Table 2). This evidence concerns the gene PLK4 and glioblastoma.